Aliso Viejo, CA – September 30, 2014 – GE Healthcare today announced an agreement between its affiliate, Clarient Diagnostic Services, Inc. (Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. The collaboration […]
Cobimetinib plus Zelboraf reduced the risk of disease worsening by half compared to Zelboraf alone Phase III coBRIM study results will be presented today during the Presidential Symposium at the European Society of Medical Oncology (ESMO) 2014 Congress and published in the New England Journal of Medicine Roche has submitted an EU marketing authorisation application […]
Final data from Phase III CLEOPATRA study showed people with previously untreated HER2-positive metastatic breast cancer who received Perjeta, Herceptin and docetaxel chemotherapy lived a median of 56.5 months compared to 40.8 months for people who received Herceptin and chemotherapy1 Median overall survival of almost five years is the longest observed to date in people […]
Program expands access to care supporting the Diagnostics Access Iniative Basel, 26 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new Global Access Program for HIV viral load testing, created in partnership with UNAIDS, the joint United Nations Program on HIV/AIDS, the Clinton Health Access Initiative (CHAI), the […]
U.S. and EU Filings Planned for Q4 2014 FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 24, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives. The […]
12-Week Course of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) in Japanese Phase 3 Study Ledipasvir/Sofosbuvir Simplifies Hepatitis C Treatment to a Single, Once-Daily Tablet FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 24, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has submitted a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency […]
New Amersham™ WB system for reproducible and quantitative protein analysis The first fully-integrated system based on the traditional Western blotting technique which achieves reliably consistent results with fewer repeats and control experiments Chalfont St Giles, UK — 23 September 2014 – GE Healthcare Life Sciences (NYSE:GE) today launched Amersham WB system, a fully integrated system […]
WAUKESHA, Wis. — September 22, 2014 — GE Healthcare today announced U.S. FDA 510(k) clearance of its Discovery* IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation to help physicians deliver the best possible patient outcomes. Physicians not only want the ability to detect smaller lesions, but also the ability to determine whether […]
ABERDEEN, Scotland and SINGAPORE, 22 September 2014 – TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease. This multi-centre, placebo-controlled clinical trial (Protocol TRx-237-005) is aimed at […]
The new Elecsys anti-Müllerian Hormone (AMH) fertility test increases the accuracy of ovarian reserve assessment compared to conventional methods Basel, 18 September 2014 – Roche today announced the launch of the Elecsys Anti-Müllerian Hormone (AMH) blood test, the first fully-automated AMH test for assessing a woman’s ovarian reserve. AMH is an important fertility marker used […]